In the studies on GLP-1 Ras and visceral fat and liver fat, three recent meta-analyses showed that, for type 2 diabetes and NAFLD, regardless of the choice of exenatide or liraglutide intervention treatment, the results indicated that visceral adipose tissue and hepatic fat content were generally significantly decreased compared to other medications, placebos, and lifestyle interventions [16–18]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.